Minimal Change Disease Associated With Durvalumab

Toda, Masataro; Fujii, Kentarou; Kato, Atsushi; Yoshifuji, Ayumi; Komatsu, Motoaki; Amino, Yoshiaki; Kitazono, Satoru; Hashiguchi, Akinori; Ryuzaki, Munekazu

doi:10.1016/j.ekir.2021.08.021

Cited by 7 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most patients had full (31%) or partial (42%) recovery from AKI, although 19% remained dialysis dependent and approximately one-third died. Since then, several other glomerular pathologies have been reported and observed (our unpublished observations) in clinical practice — such as membranous nephropathy and other podocytopathies ( 4 ) ( Figure 1 ).…”

Section: To the Editormentioning

confidence: 68%

Does treating with anti–PD-1 to improve glomerular health come without a cost?

Jhaveri¹,

Kitchlu²,

Abudayyeh³

2022

Journal of Clinical Investigation

View full text Add to dashboard Cite

Section: To the Editormentioning

confidence: 68%

Does treating with anti–PD-1 to improve glomerular health come without a cost?

Jhaveri¹,

Kitchlu²,

Abudayyeh³

2022

Journal of Clinical Investigation

View full text Add to dashboard Cite

“…In terms of durvalumab, there was a presented case of a patient who developed a nephrotic syndrome with MCD confirmed in a histological examination. The patient was treated with prednisolone and his symptoms withdrew [ 81 ]. In a phase II trial that included 88 patients treated with avelumab for chemotherapy-refractory metastatic Merkel cell carcinoma, four episodes of AKI occurred [ 82 ].…”

Section: Immune Checkpoint Inhibitors (Icis)mentioning

confidence: 99%

Adverse Renal Effects of Anticancer Immunotherapy: A Review

Borówka

Łącki-Zynzeling

Nicze

et al. 2022

Cancers

View full text Add to dashboard Cite

Modern oncological therapy utilizes various types of immunotherapy. Immune checkpoint inhibitors (ICIs), chimeric antigen receptor T cells (CAR-T) therapy, cancer vaccines, tumor-targeting monoclonal antibodies (TT-mAbs), bispecific antibodies and cytokine therapy improve patients’ outcomes. However, stimulation of the immune system, beneficial in terms of fighting against cancer, generates the risk of harm to other cells in a patient’s body. Kidney damage belongs to the relatively rare adverse events (AEs). Best described, but still, superficially, are renal AEs in patients treated with ICIs. International guidelines issued by the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) cover the management of immune-related adverse events (irAEs) during ICI therapy. There are fewer data concerning real occurrence and possible presentations of renal adverse drug reactions of other immunotherapeutic methods. This implies the need for the collection of safety data during ongoing clinical trials and in the real-life world to characterize the hazard related to the use of new immunotherapies and management of irAEs.

show abstract

“…Since then, several other glomerular pathologies have been reported and observed (unpublished) in clinical practice such as MN, mesangioproliferative glomerulonephritis and other podocytopathies. [80][81][82][83] (Figure 3).…”

Section: Glomerular Diseases and Cancer Updatementioning

confidence: 99%

“…80 Since then, several other glomerular pathologies have been reported and observed (unpublished) in clinical practice such as MN, mesangioproliferative GN, and other podocytopathies (Figure 3). [80][81][82][83] Treatment of glomerular diseases associated with ICI is challenging.…”

Section: Glomerular Diseases and Cancer Updatementioning

confidence: 99%

Onconephrology 2022: An Update

et al. 2022

View full text Add to dashboard Cite

Onconephrology is an upcoming and expanding subspecialty that deals with the intersections between hematology/oncology and nephrology. With the paradigm shift in the understanding of cancer immunobiology and mechanisms of onco-therapeutic drug toxicities, it is important for a nephrologist to have a sound understanding of this field. Over the last 5 years, there have been immense developments in our understanding of kidney related adverse events from various targeted, immuno and cellular-based therapies. Pathogenic mechanisms of electrolyte imbalance, hypertension (Onco-hypertension), and acute kidney injury from multiple forms of cancer therapies have been explored. Significant research has also been conducted in the field of transplant onconephrology. In this review, we have tried to assimilate the most recent updates in the last 2 years in this ever-growing and fascinating field.

show abstract

Minimal Change Disease Associated With Durvalumab

Cited by 7 publications

References 5 publications

Does treating with anti–PD-1 to improve glomerular health come without a cost?

Does treating with anti–PD-1 to improve glomerular health come without a cost?

Adverse Renal Effects of Anticancer Immunotherapy: A Review

Onconephrology 2022: An Update

Contact Info

Product

Resources

About